The United States Food and Drug Administration (USFDA) has completed its inspection of the Sellersville, Pennsylvania, manufacturing facility of Piramal Pharma, the company announced on April 19.
According to Piramal Pharma, the US health regulator issued an Establishment Inspection Report (EIR) for its Sellersville, Pennsylvania manufacturing facility. EIR is the ultimate inspection report generated by the FDA.
Piramal Pharma claimed the USFDA approved an EIR for its Sellersville manufacturing site.
Between December 19, 2022 and January 13, 2023, the inspection was conducted.
The Sellersville facility of Piramal Pharma is a fully integrated facility that manufactures and packages solid oral dosage forms, liquids, lotions, and ointments.
In February, USFDA issued an EIR for the Lexington division of Piramal Pharma.
